Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: A prospective study by the Finnish Lymphoma Group

Leukemia and Lymphoma

Volumn 53, Issue 10, 2012, Pages 1920-1928

  Räty, Riikka ^a   Honkanen, Tuomo ^b   Jantunen, Esa ^c   Jyrkkiö, Sirkku ^d   Karjalainen Lindsberg, Marja Liisa ^a   Kuittinen, Outi ^e   Lehto, Minna ^b   Mikkola, Maija ^f   Poikonen, Eira ^a   Rauhala, Auvo ^g   Rimpiläinen, Johanna ^h   Räsänen, Anu ⁱ   Siitonen, Sanna ^a   Suominen, Merja ^j   Vapaatalo, Mirja ^a   Elonen, Erkki ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b Department of Medicine   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e OULU UNIVERSITY HOSPITAL   (Finland)

^f MIKKELI CENTRAL HOSPITAL   (Finland)

^g VAASA CENTRAL HOSPITAL   (Finland)

^h NORTH KARELIA CENTRAL HOSPITAL   (Finland)

ⁱ KYMENLAAKSO CENTRAL HOSPITAL   (Finland)

^j KANTA HÄME CENTRAL HOSPITAL   (Finland)

more..

Author keywords

Cytarabine; Elderly patients; Fludarabine; Immunochemotherapy; Maintenance; Mantle cell lymphoma; Outcome; Rituximab; Toxicity

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FLUDARABINE; FLUDARABINE PHOSPHATE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ACUTE HEART INFARCTION; AGED; AGED HOSPITAL PATIENT; BRONCHIECTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DIZZINESS; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; INDUCTION CHEMOTHERAPY; INFECTION; KIDNEY DISEASE; LIVER DISEASE; LONG TERM CARE; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MANTLE CELL LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESPIRATORY TRACT INFECTION; REVIEW; SCORING SYSTEM; SIDE EFFECT; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; LYMPHOMA, MANTLE-CELL; MAINTENANCE CHEMOTHERAPY; MALE; PREDNISONE; TREATMENT OUTCOME; VIDARABINE; VINCRISTINE;

EID: 84865725149     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.672736     Document Type: Review

References (49)

1. Geisler CH, Kolstad A, Laurell A, et al. Long-term progressionfree survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112:2687-2693.
2. Hermine O, Hoster E, Walewski J, et al. Alternating courses of 3x CHOPand 3x DHAPplus rituximab followed by a high dose Ara-Ccontaining myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOPplus rituximab followed by myeloablative radiochemotherapy and ASCTin mantle cell lymphoma; results of the MCLyounger trial of the European Mantle Cell Lymphoma Network. Blood 2010;116(SUPPL. 1): Abstract 110.
3. Zucca E, Roggero E, Pinotti G, et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995;6:257-262.
4. Samaha H, Dumontet C, Ketterer N, et al. Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia 1998;12:1281-1287.
5. Oinonen R, Franssila K, Teerenhovi L, et al. Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients. Eur JCancer 1998;34:329-336.
6. Räty R, Franssila K, Joensuu H, et al. Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur JHaematol 2002;69:11-20.
7. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. JClin Oncol 2009;27:511-518.
8. Abrahamsson A, Dahle N, Jerkeman M. Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry. Leuk Lymphoma 2011;52: 1929-1935.
9. Griffiths R, Mikhael J, Gleeson M, et al. Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. Blood 2011;118: 4808-4816.
10. Foran JM, Cunningham D, Coiffier B, et al. Treatment of mantlecell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol 2000;11(SUPPL. 1):117-121.
11. Ghielmini M, Schmitz SF, Burki K, et al. The effect of rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2000;11(SUPPL. 1): 123-126.
12. Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOPinduction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. JClin Oncol 2002;20:1288-1294.
13. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). JClin Oncol 2005;23:1984-1992.
14. Lenz G, Hiddemann W, Dreyling M. The role of fludarabine in the treatment of follicular and mantle cell lymphoma. Cancer 2004;101:883-893.
15. Di Gaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br JHaematol 2001;114: 800-809.
16. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCMalone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004;104:3064-3071.
17. Gianni AM, Cortelazzo S, Magni M, et al. Rituximab: enhancing stem cell transplantation in mantle cell lymphoma. Bone Marrow Transplant 2002;29(SUPPL. 1):S10-S13.
18. Geisler CH, Elonen E, Kolstad A, et al. Nordic Mantle Cell Lymphoma (MCL) Project: prolonged follow-up of 86 patients treated with BEAM/BEAC PBSCTconfirms that addition of high-dose Ara-Cand rituximab to CHOPinduction+in-vivo purging with rituximab increases clinical and molecular response rates, PCR-neg. grafts, failure-free, relapse-free and overall survival. Blood 2004; 104(SUPPL. 1):8.
19. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108:4003-4008.
20. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295-3301.
21. Vidal L, Gafter-Gvili A, Salles G, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. JNatl Cancer Inst 2011;103:1799-1806.
22. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011;377:42-51.
23. Kluin-Nelemans J, Hoster E, Vehling-Kaiser U, et al. Rituximab maintenance significantly prolongs duration of remission in elderly patients with mantle cell lymphoma. First results of a randomized trial of The European MCLNetwork. Haematologica 2011;96(SUPPL.): Abstract 504.
24. Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVADand highdose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. JClin Oncol 1998;16:3803-3809.
25. Romaguera JE, Khouri IF, Kantarjian HM, et al. Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma 2000;39:77-85.
26. Lefrere F, Delmer A, Suzan F, et al. Sequential chemotherapy by CHOPand DHAPregimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002;16:587-593.
27. Gandhi V, Estey E, Du M, et al. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy. Clin Cancer Res 1997;3:1539-1545.
28. Hoster E, Dreyling M, Klapper W, et al. Anew prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111:558-565.
29. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. JClin Oncol 2007;25:579-586.
30. Kluin-Nelemans JC, Hoster E, Hermine O, et al. R-CHOPversus R-FCfollowed by maintenance with rituximab or IFN: first results of a randomized trial for elderly patients with mantle cell lymphoma. Ann Oncol 2011;22(SUPPL.): Abstract 16.
31. Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOPrituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. JClin Oncol 2011;29:690-697.
32. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantlecell lymphoma with rituximab plus hyper-CVADalternating with rituximab plus high-dose methotrexate and cytarabine. JClin Oncol 2005;23:7013-7023.
33. Romaguera JE, Fayad LE, Feng L, et al. Ten-year follow-up after intense chemoimmunotherapy with rituximab-HyperCVADalternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br JHaematol 2010;150:200-208.
34. Carney DA, Westerman DA, Tam CS, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia 2010;24:2056-2062.
35. Ghielmini M, Rufibach K, Salles G, et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response andevent-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2005;16:1675-1682.
36. Andersen NS, Pedersen LB, Laurell A, et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. JClin Oncol 2009;27: 4365-4370.
37. Solal-Celigny P. Safety of rituximab maintenance therapy in follicular lymphomas. Leuk Res 2006;30(SUPPL. 1):S16-S21.
38. Aksoy S, Harputluoglu H, Kilickap S, et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007;48:1307-1312.
39. Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore) 2010;89:308-318.
40. Cattaneo C, Spedini P, Casari S, et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma 2006;47: 1013-1017.
41. Liu JH, Wei S, Lamy T, et al. Chronic neutropenia mediated by fas ligand. Blood 2000;95:3219-3222.
42. Stamatopoulos K, Papadaki T, Pontikoglou C, et al. Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with lateonset neutropenia. Leukemia 2008;22:1446-1449.
43. Grant C, Wilson WH, Dunleavy K. Neutropenia associated with rituximab therapy. Curr Opin Hematol 2010 Nov 22. [Epub ahead of print]
44. Keane C, Nourse JP, Crooks P, et al. Homozygous FCGR3A-158Valleles predispose to late onset neutropenia after CHOP-Rfor diffuse large B-cell lymphoma. Intern Med J2011 Sep 1. [Epub ahead of print]
45. Hincks I, Woodcock BE, Thachil J. Is rituximab-induced lateonset neutropenia a good prognostic indicator in lymphoproliferatve disorders? Br JHaematol 2011;153:411-413.
46. Pott C, Schrader C, Gesk S, et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 2006;107:2271-2278.
47. Pott C, Hoster E, Delfau-Larue MH, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCLIntergroup study. Blood 2010;115:3215-3223.
48. Bö ttcher S, Ritgen M, Buske S, et al. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-colour flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations. Haematologica 2008;93:551-559.
49. Goy A, Kahl B. Mantle cell lymphoma: the promise of new treatment options. Crit Rev Oncol Hematol 2011;80:69-86.